Title: AMORPHOUS AND POLYMORPHIC FORMS OF TELMISARTAN SODIUM

Abstract: Provided is (Formula (I)) the amorphous form of telmisartan sodium and the preparation thereof. Also provided are the telmisartan sodium polymorph crystal Forms 0 to XIII and XV to XX and preparations thereof. Also provided are pharmaceutical composition of amorphous and polymorphic forms of telmisartan sodium or mixtures thereof, and methods of treatment of a mammal in need thereof.

(51) International Patent Classification:
C07D 235/20 (2006.01) A61K 9/12 (2006.01)
A61K 31/4184 (2006.01)

(21) International Application Number:
PCT/US2005/040059

(22) International Filing Date:
3 November 2005 (03.11.2005)

(25) Filing Language:
English

(26) Publication Language:
English

(30) Priority Data:
60/624,842 3 November 2004 (03.11.2004) US
60/652,246 11 February 2005 (11.02.2005) US

(71) Applicant (for all designated States except BB; US):
TEVA PHARMACEUTICAL INDUSTRIES LTD.
[IL/IL]; 5 Basel Street, P.O. Box 3190, 49131 Petah Tiqva (IL).

(71) Applicant (for BB only): TEVA PHARMACEUTICALS
USA, INC. [US/US]; 1090 Horsham Road, P.O. Box 1090,
North Wales, PA 19454 (US).

(72) Inventors:

(75) Inventors/Applicants (for US only): WIZEL, Shlomit
[IL/IL]; Yehuda Hanassi 2, 49742 Petah Tiqva (IL).
PERLMAN, Nurit [IL/IL]; 4 Moshe Dayan St., 44539
Kfar Saba (IL). AVHAR-MAYDAN, Sharon [IL/IL]; 33
Hatzanachim, Givatayim (IL). GILBOA, Eyal [IL/IL];
1B Livai Street, 59395 Bat-Yam (IL).

(84) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GL, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,
LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,
RO, SE, SI, SK, TR), OAPI (BI, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
3 August 2006

For two-letter codes and other abbreviations, refer to the “Guidance Notes on Codes and Abbreviations” appearing at the begin-
ing of each regular issue of the PCT Gazette.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D235/20 A61K31/4184 A61P9/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BEILSTEIN Data, CHEM ABS Data, WPI Data, PAJ, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>E</td>
<td>WO 2005/117837 A (TEVA GYOJYSZERGYAR RESZVENYTARSASAG; TEVA PHARMACEUTICALS USA, INC; SZ) 15 December 2005 (2005-12-15) page 8, lines 23-29; claim 1</td>
<td>1-7</td>
</tr>
<tr>
<td>P,X</td>
<td>DATABASE CAPLUS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002368790 Database accession no. 2005:568830 abstract</td>
<td>1-7</td>
</tr>
</tbody>
</table>

X Further documents are listed in the continuation of Box C. X See patent family annex.

* Special categories of cited documents:

* A document defining the general state of the art which is not considered to be of particular relevance
* E earlier document but published on or after the international filing date
* L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
* O document referring to an oral disclosure, use, exhibition or other means
* P document published prior to the international filing date but later than the priority date claimed

<table>
<thead>
<tr>
<th>Date of the actual completion of the international search</th>
<th>Date of mailing of the international search report</th>
</tr>
</thead>
<tbody>
<tr>
<td>18 May 2006</td>
<td>19/06/2006</td>
</tr>
</tbody>
</table>

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentplein 2
NL - 2280 HU Rijswijk
Tel: (+31-70) 343-2040, Tx: 31 651 epo nl,
Fax: (+31-70) 346-3016

Authorized officer

Seymour, L

Form PCT/ISA/910 (second sheet) [April 2008]
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>P,X</td>
<td>&amp; CN 1 548 421 A (SHANGHAI INST. OF MEDICINE INDUSTRY) 24 November 2004 (2004-11-24) example 1</td>
<td>1-7</td>
</tr>
</tbody>
</table>
INTERNATIONAL SEARCH REPORT

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
   Although claim 4 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. ☐ Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. ☐ Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentence of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. X As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
   1 and 2-7 (part, inventions 1-8)

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

X No protest accompanied the payment of additional search fees.
This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1, 3-7 (part)
   An amorphous form of telmisartan sodium

2. claims: 2-7 (part)
   Telmisartan sodium Form O

3. claims: 2-7 (part)
   Telmisartan sodium Form I

4. claims: 2-7 (part)
   Telmisartan sodium Form II

5. claims: 2-7 (part)
   Telmisartan sodium Form III

6. claims: 2-7 (part)
   Telmisartan sodium Form IV

7. claims: 2-7 (part)
   Telmisartan sodium Form V

8. claims: 2-7 (part)
   Telmisartan sodium Form VI

9. claims: 2-7 (part)
   Telmisartan sodium Form VII

10. claims: 2-7 (part)
    Telmisartan sodium Form VIII

11. claims: 2-7 (part)
Telmisartan sodium Form IX

12. claims: 2-7 (part)
   Telmisartan sodium Form X

13. claims: 2-7 (part)
   Telmisartan sodium Form XI

14. claims: 2-7 (part)
   Telmisartan sodium Form XII

15. claims: 2-7 (part)
   Telmisartan sodium Form XIII

16. claims: 2-7 (part)
   Telmisartan sodium Form XV

17. claims: 2-7 (part)
   Telmisartan sodium Form XVI

18. claims: 2-7 (part)
   Telmisartan sodium Form XVII

19. claims: 2-7 (part)
   Telmisartan sodium Form XVIII

20. claims: 2-7 (part)
   Telmisartan sodium Form XIX

21. claims: 2-7 (part)
   Telmisartan sodium Form XX
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>CN 1548421 A</td>
<td>24-11-2004</td>
<td>NONE</td>
<td></td>
</tr>
</tbody>
</table>